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Abstract 
Data presented here provide the first demonstration that circulating amylin regulates metabolism in vivo, and support an endocrine hormonal role 
that is distinct from its autocrine action at pancreatic islets. When rats were pre-treated with the potent amylin antagonist AC187 (n = 18), and then 
administered a 2 mm01 glucose load, the rise in plasma lactate was less than in rats administered glucose only (n = 27; P < 0.02). When rats were 
treated so that plasma glucose and insulin profiles were similar (n = 8), the increase in plasma lactate in the presence of AC187 was only 50.3% as 
high as the increase when AC187 was absent (P < 0.001). These experimental results fit with the view that some of the lactate appearing in plasma 
after a glucose load comes from insulin-sensitive tissues. The experiments also support the view that an important fraction of the increase in lactate 
depends on processes inhibited by a selective amylin antagonist, most likely amylin action in muscle. 
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1. Introduction 
Amylin is a 37-amino acid peptide [l] co-secreted with 
insulin from pancreatic /&ells. Its plasma concentration 
increases with nutrient stimuli. 
The first reported biologic action of amylin was the 
inhibition of insulin-stimulated incorporation of glucose 
into glycogen in isolated rat skeletal muscle [2]. This 
finding has been confirmed and extended in vitro [3] and 
in vivo and appears to result from activation of glycogen 
phosphorylase [4] and inhibition of glycogen synthase 
[S]. Amylin stimulation has been proposed [4] as underly- 
ing the previously unexplained increment in phosphory- 
lase a activity observed after oral glucose [6]. It was 
proposed that amylin’s actions could increase lactate 
production, and an early effect of amylin injections in 
intact rats is a rise in plasma lactate concentration [7]. 
Accordingly, we have suggested that amylin serves as a 
partner hormone with insulin [S] to promote lactate flux. 
While some authors have concluded that plasma am- 
ylin is too low to have a significant endocrine function 
[9], several studies now report metabolic actions of ex- 
ogenous amylin at reported plasma levels. However, 
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those studies have not demonstrated metabolic regula- 
tion by endogenously secreted amylin. One approach to 
determining the effects of circulating amylin, and thereby 
whether it is behaving as a hormone, is to block its action 
with selective antagonists. This experimental test has 
been made possible by our having designed and synthe- 
sized a number of potent and selective amylin receptor 
antagonists, such as ACl87, described here for the first 
time. A similar approach has been applied to the study 
of pancreatic islet function. Insulin secretion [lO-141 and 
p-cell activity [15] were reported to be inhibited by am- 
ylin, but it was not clear whether endogenously secreted 
amylin had effects on /?-cell secretion. Increased insulin 
secretion in the presence of amylin antagonists [16,171 
support the idea [16] that endogenously secreted amylin 
reduces insulin secretion. 
AC187 has been shown to have appropriate pharma- 
cologic properties in binding studies and in isolated tis- 
sues. AC187 competes potently for rat amylin binding at 
high affinity sites such as rat nucleus accumbens mem- 
branes [ 181 which have been useful in developing a num- 
ber of selective ligands, including AC187. The Kd for 
amylin at this site is 28 pM, and the Kj for AC187 is 79 
pM. AC187 is relatively selective in competing for am- 
ylin binding, displacing amylin from nucleus accumbens 
membranes with over 400-fold greater potency than it 
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displaces [‘*?]hCGRP from CGRP receptors (SK-N- 
MC cells [19]), and with 38-fold greater potency than 
that with which it displaces [‘*‘I]salmon calcitonin from 
calcitonin receptors (T47D cells [20]). Second, when 
present at 30 nM, AC187 reverses the inhibitory action 
of 100 nM rat amylin on insulin-stimulated incorpora- 
tion of [U-i4C]glucose into glycogen in isolated rat soleus 
muscle [3] by 50%. 
The first part of the present study describes the ability 
of AC187 to block the metabolic actions of exogenous 
amylin in vivo. Using this amylin antagonist, we then 
tested whether endogenously secreted amylin causes part 
of the increase in plasma lactate seen after a glucose load. 
When glucose and insulin profiles were matched, pre- 
infusion of AC187 reduced the surge in plasma lactate 
following glucose administration, indicating that the 
processes responsible for it were sensitive to normally 
circulating levels of amylin. 
2. Materials and methods 
2.1. Animals 
Male Harlan SpragueDawley rats (weight 250-350 g) were used in 
all studies. In all preparations, rats were anaesthetized with halothane, 
tracheotomized, and cammlated via the femoral artery and saphenous 
vein. A 2-h stabilization period under light anaesthesia then followed 
to allow metabolic stabilization of the preparation before recordings 
began. 
2.2. AC187 
AC1 87 (amino acid sequence N-acetyl-Val-Leu-Gly-Lys-Leu-Ser- 
Gln- Glu- Leu- His- Lys- Leu- Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly- 
Ser-Am-Thr-Tyr-NH,, MW 2890) was made in house as the TFA salt 
by solid phase peptide synthesis and puritied by reverse-phase high- 
performance liquid chromatography to a purity of 99%. Peptide con- 
tent was 74.6 f 1.4%. 
2.3. In vivo characterization of AC187 
Animals fasted for 18-20 h were anesthetized and prepared as above 
before intravenous preinfusion with either AC187 (1.5 ,umol/kg, then 
5 nmol/kg/min) or saline from t = -30 min until t = +60 min. This was 
followed by an intravenous infusion of either rat amylin (36 nmohkg, 
then 0.6 nmol/kg/min) or saline which began 30 min later at t = 0 min 
and continued throughout the experiment. There were, therefore, 
4 treatment groups: saline + saline (n = 7), saline + amylin (n = 8), 
AC187 + saline (n = 3), and AC187 + amylin (n = 4). 
2.4. Lactate responses following intravenous glucose 
Fed male Harlan SpragueDawley rats (360-420 g) were anesthetized 
and prepared as described above before intravenous administration of 
5.2 mmol/kg (2 mmol) u-glucose over 2 min. Arterial samples were 
taken at the times indicated and plasma immediately analyzed by im- 
mobilized enzyme chemistries (YSI 2300 STAT analyzer, Yellow 
Springs, OH) for glucose and lactate. Additional samples were frozen 
and subsequently analyzed by radioimmunoassay (RIA kit 06130, 
INCStar Corp, MN) for insulin. One group of rats (n = 18) was admin- 
istered the amylin antagonist AC187 as a primed/continuous infusion 
(131 nmol/kg + 4.4 nmolikg/min) from t = -10 to t = +120 min to 
block the actions of endogenous amylin. Control rats (n = 27) received 
intravenous glucose, but saline instead of AC187. Another group of rats 
(n = 8) was administered 0.1 mnol insulin (Humulin-R, Eli Lilly, India- 
napolis) by subcutaneous injection 3 min after the i.v. glucose load so 
that the plasma insulin protile would match that of the AC187-treated 
group. This control group was required because insulin secretion is 
inhibited by amylin and enhanced by amylin blockers such as 
“‘hCGRP [lq, &3ZsCalcitonin (Marco et al., unpublished) and 
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8m37rAmylin [17]. Lactate responses were integrated by the trapezoidal 
integral method for the 60 min following glucose administration and 
expressed as increments above the values obtained in rats not adminis- 
tered glucose (n = 5). 
3. Results 
3.1. In vivo characterization of AC187 
In the present in vivo study, AC1 87 was able to inhibit 
metabolic responses to exogenous amylin in the intact 
animal. Fig. 1 shows that an infusion of AC187 that was 
itself without effect on lactate levels in anesthetized rats, 
inhibited by more than 90% the lactate increment evoked 
by infusions of rat amylin. When the AC1 87 infusion was 
stopped but the amylin continued, the response typical 
of amylin agonists (an increase in lactate) returned, indi- 
cating reversibility of the antagonism. Other experiments 
(data not shown) have shown that AC187-induced 
blockade of amylin action is surmountable by higher 
doses of amylin, indicative of a competitive (surmounta- 
ble) antagonism. 
Other experiments indicate that the infusion regimen 
for AC187 used in the present preparation could be ex- 
pected to suppress the response of any endogenously 
secreted amylin. The 131 nmol/kg + 4.4 nmol/kg/min 
AC187 infusions used glucose challenge experiments of 
the present study were able to block the lactemic effects 
of 10 pg exogenous amylin injected subcutaneously. The 
incremental area under the 0 + 60 min lactate curve was 
37.7 f 3.8 mM . min compared to 52.4 f 3.8 mM . min 
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Fig. 1. Blockade of amylin-induced hyperlactemia by AC1 87. Arterial 
plasma lactate increased in rats receiving saline then amylin. Rats 
receiving AC187 then amylin showed no change in plasma lactate, a 
response similar to saline + saline infused controls and similar to rats 
receiving AC1 87 + vehicle alone. In rats receiving AC1 87 + amylin, the 
agonist response (an increase in lactate) returned when infusion of the 
antagonist was stopped. Symbols are means f S.E.M. 
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Fig. 2. Glucose, insulin and lactate concentrations following intravenous glucose administration into control, insulin-injected and AC 1874nfused 
rats. Plasma concntrations are shown in the left-hand graphs. Integrated responses, which are the area between the concentration profiles of the 
glucose-infused animals and the no-glucose (baseline) group between 0 and 60 minutes after glucose, are plotted as bars in the right-hand graphs. 
Changes in plasma glucose were equivalent in all groups, as shown by the upper bar graph. The lactate surge after glucose was increased over control 
values (lower panels; P < 0.02) when the plasma insulin profile was augmented by a subcutaneous injection. When the amylin antagonist AC187 was 
administered to block actions of endogenous amylin, the insulin response was 81% greater than the control response (middle panels; P c 0.05), 
consistent with previous interpretations that endogenous amylin tonically inhibits insulin release. The lactate response (lower panels) in AC187-infused 
animals was depressed not only below the levels observed in insulin-injected rats with matched glucose and insulin profiles (P c O.OOl), but also below 
those in control rats (P < 0.02). Symbols are means f S.E.M. The significance of differences between bars is indicated next to the relevant ies between 
bars. 
with 10 pg amylin alone (P C O.OS), and was similar to 
responses observed with saline or AC187 only 
(34.4 f 1.9 and 35.1 + 2.6, respectively; n.s.). Such 1Opg 
amylin injections produce peak plasma levels of 347 pM, 
which exceeds endogenous amylin levels observed in nor- 
mal SpragueDawley rats. 
3.2. Lactate responses following intravenous glucose 
Figure 2 shows plasma glucose, lactate and insulin 
concentrations before and after an intravenous admini- 
stration of 2 mm01 glucose alone. As expected, glucose 
rose almost immediately to a peak and then declined 
towards baseline levels. Insulin levels rose for about 15 
min and then declined over the next 2 h. As seen in the 
lower panel, lactate levels approximately doubled over 
the first 30 min and then slowly declined. 
The same experiment was performed with endogenous 
insulin release supplemented by a subcutaneous injection 
of 0.1 nmol insulin. This dose and mode of administra- 
tion increased the 0 + 60 min incremental insulin re- 
sponse by 84%, an amount that was designed to closely 
mimic (P = 0.96) the 81% increase in insulin response 
observed in the presence of amylin blockade by AC187. 
Following such insulin supplementation, the lactate 
surge was 47% higher than that seen under control con- 
ditions. 
Also shown in Fig. 2 are the responses to intravenous 
glucose under conditions where AC187 was used to 
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block the action of endogenous amylin. The change in 
plasma glucose was similar to that seen under controlled 
conditions. The incremental insulin response was some 
8 1% greater than that observed under control conditions 
(P c 0.02), consistent with results obtained from other 
studies [16,17] where amylin antagonists increased nu- 
trient-stimulated insulin secretion, as described in 
section 1. 
The lactate response are shown as shaded and open 
symbols in Fig. 2. The lactate response (change in area 
under the curve) in the presence of AC187 was only half 
of that seen when insulin levels were matched by supple- 
mental S.C. injections (P < O.OOl), and was in fact less 
than that seen under control conditions where insulin 
was lower (P < 0.02). 
4. Discussion 
The observation that added insulin increased lactate 
levels after glucose is consistent with the conventional 
view [21] that increased lactate generation is the result 
increased glycolytic flux, driven by both the increased 
glucose gradient and increases in insulin-mediated glu- 
cose transport. 
However, from this view one would also have pre- 
dicted that similar glucose and insulin profiles would 
result in similar lactate profiles. That is, with equivalent 
increases in insulin-mediated transport and in the gradi- 
ent driving glucose into cells, increases in non-oxidative 
glycolytic flux and lactate generation should also have 
been equivalent. 
In the present experiments, the glucose profiles and 
insulin profiles were well matched in the group of ani- 
mals injected with extra insulin and in the group treated 
with the amylin antagonist. In spite of this matching, the 
lactate response in the AC187-infused rats was only half 
of that observed in the insulin-injected group. 
These observations are consistent with AC1 87 having 
blocked the actions of a lactate-mobilizing agent that is 
released in response to glucose. The most likely explana- 
tion is that we have observed the effects of blocking 
endogenously released amylin. 
A conceivable alternative interpretation of the present 
data is that AC187 could have blocked a naturally-oc- 
curring ligand other than amylin which was increased in 
response to glucose administration. Some authors [22] 
have proposed that calcitonin gene-related peptide 
(CGRP) may be involved in regulating carbohydrate me- 
tabolism with amylin-like actions. How, then, can we be 
confident that it is not the effects of endogenous CGRP 
which are being blocked? First, CGRP levels have been 
reported not to increase in plasma after glucose admini- 
stration [23]. Second, the lack of any change in blood 
pressure in our experiments makes it unlikely that 
CGRP, at least systemically, was increased, since 
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CGRP’s most powerful action is on vasodilation. Third, 
AC187 is highly selective for amylin action over CGRP 
action on skeletal muscle. It has recently been deter- 
mined (Irsula et al., unpublished) that AC187 is 500-fold 
less potent in blocking the effects of CGRP on skeletal 
muscle than it is at blocking the effects of amylin on 
skeletal muscle. Because the lactate response was indeed 
blockable by AC187, the present observations are un- 
likely to result from the effects of endogenous CGRP. 
Thus, the data are most easily explained by the amylin 
receptor antagonist having blocked release of lactate 
stimulated by endogenous amylin. 
The source of lactate following a glucose load has been 
controversial. Candidate tissues have included those 
where glucose metabolism is insulin-insensitive, such as 
gut [24], as well as those where it is insulin-sensitive (fat, 
muscle and liver). A recent detailed study in conscious 
dogs [25] indicated that much of the lactate rise following 
glucose absorption appeared to come from stored carbo- 
hydrate, predicted to be muscle glycogen, and not from 
the absorbed glucose. While the techniques in the present 
study could not have determined the tissue sources of 
lactate, it is likely that they included insulin-sensitive 
tissues, since addition of insulin increased the lactate 
response. The amylin blockade experiments reported 
here, now also indicate that up to half of the lactate 
response may be derived from amylin-sensitive tissue, 
which includes muscle, but not fat [26]. 
The use of selective amylin blockade is a useful tool 
in the definition of the role of endogenous amylin. The 
present findings obtained using such an agent represent 
the first demonstration in normal animals of an endo- 
crine action of endogenous amylin that was distinct from 
an autocrine role at the pancreas, and therefore support 
an hormonal role. 
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